176 related articles for article (PubMed ID: 18080044)
1. Pain due to multiple sclerosis: analysis of the prevalence and economic burden in Canada.
Piwko C; Desjardins OB; Bereza BG; Machado M; Jaszewski B; Freedman MS; Einarson TR; Iskedjian M
Pain Res Manag; 2007; 12(4):259-65. PubMed ID: 18080044
[TBL] [Abstract][Full Text] [Related]
2. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.
Karampampa K; Gustavsson A; Miltenburger C; Kindundu CM; Selchen DH
J Popul Ther Clin Pharmacol; 2012; 19(1):e11-25. PubMed ID: 22247419
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts.
Amankwah N; Marrie RA; Bancej C; Garner R; Manuel DG; Wall R; Finès P; Bernier J; Tu K; Reimer K
Health Promot Chronic Dis Prev Can; 2017 Feb; 37(2):37-48. PubMed ID: 28273039
[TBL] [Abstract][Full Text] [Related]
4. Burden of illness of multiple sclerosis: Part I: Cost of illness. The Canadian Burden of Illness Study Group.
Can J Neurol Sci; 1998 Feb; 25(1):23-30. PubMed ID: 9532277
[TBL] [Abstract][Full Text] [Related]
5. The economic impact of multiple sclerosis in Australia in 2010.
Palmer AJ; Colman S; O'Leary B; Taylor BV; Simmons RD
Mult Scler; 2013 Oct; 19(12):1640-6. PubMed ID: 23652216
[TBL] [Abstract][Full Text] [Related]
6. Costs and quality of life of multiple sclerosis in Sweden.
Berg J; Lindgren P; Fredrikson S; Kobelt G
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S75-85. PubMed ID: 17310342
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of multiple sclerosis in the UK, Germany and France.
Murphy N; Confavreux C; Haas J; König N; Roullet E; Sailer M; Swash M; Young C; Mérot JL;
Pharmacoeconomics; 1998 May; 13(5 Pt 2):607-22. PubMed ID: 17165327
[TBL] [Abstract][Full Text] [Related]
8. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis.
Ruutiainen J; Viita AM; Hahl J; Sundell J; Nissinen H
J Med Econ; 2016; 19(1):21-33. PubMed ID: 26360615
[TBL] [Abstract][Full Text] [Related]
9. The burden of multiple sclerosis in Japan.
Nohara C; Hase M; Liebert R; Wu N
J Med Econ; 2017 Dec; 20(12):1290-1298. PubMed ID: 28849983
[TBL] [Abstract][Full Text] [Related]
10. Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US.
Jones E; Pike J; Marshall T; Ye X
BMC Health Serv Res; 2016 Jul; 16():294. PubMed ID: 27443278
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.
da Silva NL; Takemoto MLS; Damasceno A; Fragoso YD; Finkelsztejn A; Becker J; Gonçalves MVM; Tilbery C; de Oliveira EML; Callegaro D; Boulos FC
BMC Health Serv Res; 2016 Mar; 16():102. PubMed ID: 27009599
[TBL] [Abstract][Full Text] [Related]
12. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands.
Karampampa K; Gustavsson A; van Munster ET; Hupperts RM; Sanders EA; Mostert J; Sinnige OL; de Graaf J; Pop P; Miltenburger C; Groot MT; Relleke M; van der Hel WS
J Med Econ; 2013 Jul; 16(7):939-50. PubMed ID: 23692584
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Physician Therapeutic Inertia for Management of Patients With Multiple Sclerosis in Canada, Argentina, Chile, and Spain.
Almusalam N; Oh J; Terzaghi M; Maurino J; Bakdache F; Montoya A; Caceres F; Saposnik G
JAMA Netw Open; 2019 Jul; 2(7):e197093. PubMed ID: 31314113
[TBL] [Abstract][Full Text] [Related]
14. Direct and indirect economic consequences of multiple sclerosis in Ireland.
Fogarty E; Walsh C; McGuigan C; Tubridy N; Barry M
Appl Health Econ Health Policy; 2014 Dec; 12(6):635-45. PubMed ID: 25227118
[TBL] [Abstract][Full Text] [Related]
15. The cost of multiple sclerosis in Australia.
Taylor B; McDonald E; Fantino B; Sedal L; MacDonnell R; Pittas F; Groom T; Beresniak A
J Clin Neurosci; 2007 Jun; 14(6):532-9. PubMed ID: 17430777
[TBL] [Abstract][Full Text] [Related]
16. Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability.
Casado V; Martínez-Yélamos S; Martínez-Yélamos A; Carmona O; Alonso L; Romero L; Moral E; Gubieras L; Arbizu T
BMC Health Serv Res; 2006 Nov; 6():143. PubMed ID: 17078879
[TBL] [Abstract][Full Text] [Related]
17. Costs and quality of life of multiple sclerosis in Germany.
Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
[TBL] [Abstract][Full Text] [Related]
18. Economic consequences of multiple sclerosis for Canadians.
Asche CV; Ho E; Chan B; Coyte PC
Acta Neurol Scand; 1997 May; 95(5):268-74. PubMed ID: 9188900
[TBL] [Abstract][Full Text] [Related]
19. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
20. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Turkey.
Karabudak R; Karampampa K; Calışkan Z;
J Med Econ; 2015 Jan; 18(1):69-75. PubMed ID: 25116693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
